Levalbuterol structure
|
Common Name | Levalbuterol | ||
---|---|---|---|---|
CAS Number | 34391-04-3 | Molecular Weight | 239.311 | |
Density | 1.2±0.1 g/cm3 | Boiling Point | 433.5±40.0 °C at 760 mmHg | |
Molecular Formula | C13H21NO3 | Melting Point | N/A | |
MSDS | N/A | Flash Point | 159.5±17.9 °C |
Use of LevalbuterolLevalbuterol ((R)-Albuterol; (R)-Salbutamol) is a short-acting β2-adrenergic receptor agonist and the active (R)-enantiomer of Salbutamol. Levalbuterol is a more potent bronchodilator than Salbutamol and has the potential for the treatment of COPD[1]. |
Name | (R)-salbutamol |
---|---|
Synonym | More Synonyms |
Description | Levalbuterol ((R)-Albuterol; (R)-Salbutamol) is a short-acting β2-adrenergic receptor agonist and the active (R)-enantiomer of Salbutamol. Levalbuterol is a more potent bronchodilator than Salbutamol and has the potential for the treatment of COPD[1]. |
---|---|
Related Catalog | |
In Vitro | Levalbuterol (10 μM; 24 hours) induces 11β-HSD1 mRNA expression, however, it does not influence 11β-HSD2expression in airway epithelial cells[1]. Levalbuterol (10 μM; 24 hours) significantly reduces both LPS- and TNF-α-induced NF-κB activity while increasing GRE activation in an 11β-HSD1 dependent manner in a transformed mouse airway epithelial cell line[1]. RT-PCR[1] Cell Line: Murine Club (MTCC) cells Concentration: 10 μM Incubation Time: 24 hours Result: Increased 11β-HSD1 mRNA expression selectively. |
In Vivo | Levalbuterol (subcutaneous injection; 1 mg/kg; 14 days) significantly decreases pulmonary inflammation in OVA mice, demonstrated a decrease in eosinophilia and IgE[3]. Animal Model: C57BL/6 female mice with a pulmonary allergic model[3] Dosage: 1 mg/kg Administration: Subcutaneous injection; 1 mg/kg; 14 days Result: Decreased pulmonary inflammation after OVA sensitization. |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 433.5±40.0 °C at 760 mmHg |
Molecular Formula | C13H21NO3 |
Molecular Weight | 239.311 |
Flash Point | 159.5±17.9 °C |
Exact Mass | 239.152145 |
PSA | 72.72000 |
LogP | 0.01 |
Vapour Pressure | 0.0±1.1 mmHg at 25°C |
Index of Refraction | 1.566 |
Storage condition | 2-8°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Hazard Codes | Xn: Harmful; |
---|---|
Risk Phrases | R22 |
Safety Phrases | S36 |
HS Code | 2922509090 |
~93% Levalbuterol CAS#:34391-04-3 |
Literature: Merli, Valeriano; Mantovani, Silvia; Bianchi, Stefano; Daverio, Paola Patent: US2005/261368 A1, 2005 ; Location in patent: Page/Page column 7 ; |
~95%
Detail
|
Literature: Merli, Valeriano; Mantovani, Silvia; Bianchi, Stefano; Daverio, Paola Patent: US2005/261368 A1, 2005 ; Location in patent: Page/Page column 8-10 ; |
~10% Levalbuterol CAS#:34391-04-3 |
Literature: Fine Chemical Corporation Limited Patent: US6365756 B1, 2002 ; Location in patent: Example 13 ; |
Precursor 3 | |
---|---|
DownStream 0 |
HS Code | 2922509090 |
---|---|
Summary | 2922509090. other amino-alcohol-phenols, amino-acid-phenols and other amino-compounds with oxygen function. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
(-)-Albuterol |
(R)-albuterol |
R-Albuterol |
Levosalbutamol |
(a1R)-a1-[[(1,1-Dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol |
(l)-albuterol |
(R)-a1-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-a,a'-diol |
1,3-Benzenedimethanol, α-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-, (αR)- |
(-)-a1-(((1,1-Dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol |
(R)-salbutamol |
4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol |
2-(Hydroxymethyl)-4-{(1R)-1-hydroxy-2-[(2-methyl-2-propanyl)amino]ethyl}phenol |
R-Salbutamol |
UNII-EDN2NBH5SS |
(-)-Salbutamol |
Levalbuterol |
Albuterol |
MFCD00869868 |
1,3-Benzenedimethanol, α1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, (α1R)- |
Salbutamol |